Form 8-K - Current report:
SEC Accession No. 0000950170-22-021479
Filing Date
2022-11-03
Accepted
2022-11-03 06:06:21
Documents
14
Period of Report
2022-11-03
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K bdsx-20221103.htm   iXBRL 8-K 57706
2 EX-99.1 bdsx-ex99_1.htm EX-99.1 362256
3 GRAPHIC img189760734_0.jpg GRAPHIC 3310
  Complete submission text file 0000950170-22-021479.txt   567091

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT bdsx-20221103_pre.xml EX-101.PRE 11494
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT bdsx-20221103_lab.xml EX-101.LAB 18510
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT bdsx-20221103.xsd EX-101.SCH 2462
8 EXTRACTED XBRL INSTANCE DOCUMENT bdsx-20221103_htm.xml XML 4881
Mailing Address 2970 WILDERNESS PLACE SUITE 100 BOULDER CO 80301
Business Address 2970 WILDERNESS PLACE SUITE 100 BOULDER CO 80301 303-417-0500
BIODESIX INC (Filer) CIK: 0001439725 (see all company filings)

EIN.: 203986492 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39659 | Film No.: 221355990
SIC: 8071 Services-Medical Laboratories